Exelixis (NASDAQ:EXEL) EVP Dana Aftab Sells 43,451 Shares

Exelixis, Inc. (NASDAQ:EXEL) EVP Dana Aftab sold 43,451 shares of the company’s stock in a transaction on Tuesday, May 26th. The stock was sold at an average price of $50.35, for a total transaction of $2,187,757.85. Following the sale, the executive vice president directly owned 594,741 shares of the company’s stock, valued at $29,945,209.35. The trade was a 6.81% decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at the SEC website.

Exelixis Stock Up 2.8%

Shares of Exelixis stock traded up $1.42 during trading hours on Thursday, reaching $51.45. 3,572,185 shares of the company’s stock were exchanged, compared to its average volume of 2,731,498. Exelixis, Inc. has a 1 year low of $33.76 and a 1 year high of $52.96. The company has a market capitalization of $12.93 billion, a P/E ratio of 17.09, a price-to-earnings-growth ratio of 1.06 and a beta of 0.38. The business has a fifty day moving average of $45.64 and a two-hundred day moving average of $44.10.

Exelixis (NASDAQ:EXEL) last released its earnings results on Tuesday, May 5th. The biotechnology company reported $0.87 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $0.75 by $0.12. Exelixis had a net margin of 35.08% and a return on equity of 39.89%. The business had revenue of $610.81 million during the quarter, compared to analyst estimates of $607.51 million. During the same quarter in the prior year, the firm earned $0.55 earnings per share. The company’s revenue for the quarter was up 10.0% compared to the same quarter last year. As a group, research analysts predict that Exelixis, Inc. will post 3.15 EPS for the current year.

Wall Street Analysts Forecast Growth

A number of equities research analysts have recently issued reports on the stock. HC Wainwright upped their target price on shares of Exelixis from $54.00 to $56.00 and gave the stock a “buy” rating in a report on Thursday, May 7th. Zacks Research lowered shares of Exelixis from a “strong-buy” rating to a “hold” rating in a report on Thursday, March 5th. Wells Fargo & Company upped their price objective on shares of Exelixis from $35.00 to $40.00 and gave the company an “equal weight” rating in a report on Wednesday, May 6th. Barclays upped their price objective on shares of Exelixis from $44.00 to $45.00 and gave the company an “equal weight” rating in a report on Monday, April 20th. Finally, Morgan Stanley upped their price objective on shares of Exelixis from $49.00 to $50.00 and gave the company an “equal weight” rating in a report on Wednesday, May 6th. One research analyst has rated the stock with a Strong Buy rating, nine have issued a Buy rating, eleven have given a Hold rating and two have issued a Sell rating to the stock. Based on data from MarketBeat, Exelixis has an average rating of “Hold” and an average price target of $47.35.

Institutional Inflows and Outflows

A number of large investors have recently bought and sold shares of EXEL. AQR Capital Management LLC lifted its position in shares of Exelixis by 48.8% during the fourth quarter. AQR Capital Management LLC now owns 13,658,388 shares of the biotechnology company’s stock worth $598,647,000 after purchasing an additional 4,477,029 shares in the last quarter. Farallon Capital Management LLC lifted its position in shares of Exelixis by 21.6% during the third quarter. Farallon Capital Management LLC now owns 19,501,500 shares of the biotechnology company’s stock worth $805,412,000 after purchasing an additional 3,466,000 shares in the last quarter. Assetmark Inc. lifted its position in shares of Exelixis by 1,230.8% during the third quarter. Assetmark Inc. now owns 3,195,971 shares of the biotechnology company’s stock worth $131,994,000 after purchasing an additional 2,955,813 shares in the last quarter. Norges Bank acquired a new stake in shares of Exelixis during the fourth quarter worth about $106,460,000. Finally, Allianz Asset Management GmbH lifted its position in shares of Exelixis by 153.3% during the third quarter. Allianz Asset Management GmbH now owns 2,462,948 shares of the biotechnology company’s stock worth $101,720,000 after purchasing an additional 1,490,520 shares in the last quarter. Institutional investors and hedge funds own 85.27% of the company’s stock.

More Exelixis News

Here are the key news stories impacting Exelixis this week:

• Positive Sentiment: Zacks Research raised its Q2 2026 EPS estimate for Exelixis to $0.75 from $0.72, reinforcing expectations that the company can continue delivering solid profitability.
• Positive Sentiment: Exelixis is set to participate in upcoming June investor conferences, which can help keep attention on the stock and provide new updates on pipeline and commercial progress. Article Title
• Positive Sentiment: A recent article argued that profitable, cash-generative biotech names like Exelixis may benefit as investors rotate away from expensive growth stocks and toward defensive healthcare ideas. Article Title
• Positive Sentiment: At the company’s annual meeting, investors backed the board, equity plan, and executive pay, signaling governance support and reducing uncertainty. Article Title
• Neutral Sentiment: Exelixis presented at Bernstein’s Strategic Decisions Conference, which keeps the company visible to institutional investors but did not include any major new operating update. Article Title
• Neutral Sentiment: A short-interest report showed essentially no short interest in Exelixis, suggesting limited bearish positioning but not a meaningful catalyst on its own.
• Negative Sentiment: EVP Dana Aftab sold 43,451 shares at an average price of $50.35, a disclosed insider sale that can weigh on sentiment even though the executive still holds a large position. Article Title

Exelixis Company Profile

Exelixis, Inc is a biotechnology company specializing in the discovery, development and commercialization of small molecule therapies primarily for the treatment of cancer. Building on a platform that leverages model organism genetics and high-throughput screening, the company focuses its research on kinase inhibitors that modulate critical signaling pathways involved in tumor growth and metastasis. Exelixis’s translational research approach aims to advance novel compounds from early-stage discovery through clinical development and regulatory approval.

The company’s most recognized products include CABOMETYX® (cabozantinib), approved for the treatment of advanced renal cell carcinoma and hepatocellular carcinoma, and COMETRIQ® (cabozantinib) for metastatic medullary thyroid cancer.